Retension director Donald Olds reports option holdings

Q: How many common shares underlie Donald Olds's RTSN stock options?

Donald Olds's two direct stock-option positions cover 40,258 and 24,155 underlying common shares. Their respective exercise prices are $1.43 and $2.43 per share, and their expiration dates are September 22, 2034, and October 30, 2035.

Q: What are the RTSN Series A preferred stock conversion terms?

Donald Olds directly holds 5,637 Series A Convertible Preferred Stock shares. Each is convertible into one common share at the holder's option at any time; the preferred stock automatically converts immediately before the closing of the issuer's initial public offering into 5,637 common shares without payment of consideration and has no expiration date.

The Series A preferred stock converts into one common share per preferred share and automatically converts before an IPO closes.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. director Donald Olds reported direct holdings on October 8, 2026, including stock options covering 40,258 common shares at an exercise price of $1.43 per share, expiring September 22, 2034, and options covering 24,155 common shares at $2.43 per share, expiring October 30, 2035. He also reported 5,637 Series A Convertible Preferred Stock shares, convertible into one common share each and automatically converting immediately before the closing of the issuer’s initial public offering without payment of consideration.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Olds Donald

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) ^F1	--	--	--
holding	Stock Option (right to buy) ^F2	--	--	--
holding	Series A Convertible Preferred Stock ^F3	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 64,413 contracts (Direct); Series A Convertible Preferred Stock — 5,637 contracts (Direct)

Footnotes (3)

F1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on December 21, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

Key Figures

Underlying common shares: 40,258 shares Exercise price: $1.43 per share Option expiration: September 22, 2034 +5 more

8 metrics

Underlying common shares 40,258 shares Direct stock options

Exercise price $1.43 per share Direct stock options covering 40,258 underlying common shares

Option expiration September 22, 2034 Direct stock options covering 40,258 underlying common shares

Underlying common shares 24,155 shares Direct stock options

Exercise price $2.43 per share Direct stock options covering 24,155 underlying common shares

Option expiration October 30, 2035 Direct stock options covering 24,155 underlying common shares

Series A Convertible Preferred Stock 5,637 shares Direct holdings; each converts into one common share

Conversion ratio 1 common share per preferred share Series A Convertible Preferred Stock

Key Terms

vest in 1/36 monthly increments, Stock Option (right to buy), Series A Convertible Preferred Stock, initial public offering

4 terms

vest in 1/36 monthly increments technical

"options vest in 1/36 monthly increments"

Stock Option (right to buy) financial

"Stock Option (right to buy)"

Series A Convertible Preferred Stock financial

"Series A Convertible Preferred Stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

initial public offering financial

"closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many common shares underlie Donald Olds's RTSN stock options?

Donald Olds's two direct stock-option positions cover 40,258 and 24,155 underlying common shares. Their respective exercise prices are $1.43 and $2.43 per share, and their expiration dates are September 22, 2034, and October 30, 2035.

What are the RTSN Series A preferred stock conversion terms?

Donald Olds directly holds 5,637 Series A Convertible Preferred Stock shares. Each is convertible into one common share at the holder's option at any time; the preferred stock automatically converts immediately before the closing of the issuer's initial public offering into 5,637 common shares without payment of consideration and has no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/13/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/08/2026 - 06:36 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Olds Donald

(Last)

(First)

(Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH

22046

(City)

(State)

(Zip)

QUEBEC, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/08/2026

3. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	09/22/2034	Common Stock	40,258	$1.43	D
Stock Option (right to buy)	⁽²⁾	10/30/2035	Common Stock	24,155	$2.43	D
Series A Convertible Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	5,637	⁽³⁾	D

Explanation of Responses:

1. Granted to the Reporting Person on September 23, 2024. The stock options vest in 1/36 monthly increments, with the first vesting date on December 21, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date.

2. Granted to the Reporting Person on October 31, 2025. The stock options vest in 1/36 monthly increments, with the first vesting date on September 29, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

3. The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into one share of Common Stock at any time at the option of the holder. The Series A Preferred Stock will automatically convert immediately prior to the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Alex Schwartz, Attorney-in-fact	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR